Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines
- PMID: 12111121
- PMCID: PMC11034252
- DOI: 10.1007/s00262-002-0277-3
Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines
Abstract
Previous studies have indicated that different effector cells are required to eliminate MUC1-expressing tumors derived from different organ sites and that different vaccine strategies may be necessary to generate these two different MUC1-specific immune responses. In this study, we characterized molecular components that are required to produce immune responses that eliminate Panc02.MUC1 tumors in vivo by utilizing mice genetically deficient in molecules related to immunity. A parallel study has been reported for a B16.MUC1 tumor model. We confirmed that a CD8(+) effector cell was required to eliminate MUC1-expressing Panc02 tumors, and demonstrated that T cells expressing TCR-alpha/beta and co-stimulation through CD28 and CD40:CD40L interactions played critical roles during the initiation of the anti-Panc02.MUC1 immune response. TCR-alpha/beta(+) cells were required to eliminate Panc02.MUC1 tumors, while TCR-gamma/delta(+) cells played a suppressive non-MUC1-specific role in anti-Panc02 tumor immunity. Type 1 cytokine interferon-gamma (IFN-gamma), but not interleukin-12 (IL-12), was essential for eliminating MUC1-expressing tumors, while neither IL-4 nor IL-10 (type 2 cytokines) were required for tumor rejection. In vitro studies demonstrated that IFN-gamma upregulated MHC class I, but not MHC class II, on Panc02.MUC1 tumor cells. Surprisingly, both perforin and FasL played unique roles during the effector phase of immunity to Panc02.MUC1, while lymphotoxin-alpha, but not TNFR-1, was required for immunity against Panc02.MUC1 tumors. The findings presented here and in parallel studies of B16.MUC1 immunity clearly demonstrate that different effector cells and cytolytic mechanisms are required to eliminate MUC1-expressing tumors derived from different organ sites, and provide insight into the immune components required to eliminate tumors expressing the same antigen but derived from different tissues.
Similar articles
-
MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses.Int Immunol. 2002 Aug;14(8):873-82. doi: 10.1093/intimm/dxf053. Int Immunol. 2002. PMID: 12147624
-
Antigen-primed CD8+ T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin-, CD95L-, TNFR1-, and TRAIL-dependent killing.Blood. 2003 May 15;101(10):3991-9. doi: 10.1182/blood-2002-09-2859. Epub 2003 Jan 9. Blood. 2003. PMID: 12521999
-
Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.J Immunol. 2004 Feb 1;172(3):1380-90. doi: 10.4049/jimmunol.172.3.1380. J Immunol. 2004. PMID: 14734713
-
A knockout approach to understanding CD8+ cell effector mechanisms in adaptive immunity to Listeria monocytogenes.Immunobiology. 1999 Dec;201(2):196-204. doi: 10.1016/S0171-2985(99)80059-X. Immunobiology. 1999. PMID: 10631568 Review.
-
Unusual patterns of alloimmunity evoked by allogeneic liver parenchymal cells.Immunol Rev. 2000 Apr;174:260-79. doi: 10.1034/j.1600-0528.2002.017409.x. Immunol Rev. 2000. PMID: 10807522 Review.
Cited by
-
Increased Adiposity Enhances the Accumulation of MDSCs in the Tumor Microenvironment and Adipose Tissue of Pancreatic Tumor-Bearing Mice and in Immune Organs of Tumor-Free Hosts.Nutrients. 2019 Dec 10;11(12):3012. doi: 10.3390/nu11123012. Nutrients. 2019. PMID: 31835454 Free PMC article.
-
Emerging trends in the immunotherapy of pancreatic cancer.Cancer Lett. 2018 Mar 28;417:35-46. doi: 10.1016/j.canlet.2017.12.012. Epub 2017 Dec 12. Cancer Lett. 2018. PMID: 29242097 Free PMC article. Review.
-
Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1).Cancer Immunol Immunother. 2004 Dec;53(12):1068-84. doi: 10.1007/s00262-004-0557-1. Cancer Immunol Immunother. 2004. PMID: 15696607 Free PMC article.
-
Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.Cancer Immunol Immunother. 2014 Feb;63(2):161-74. doi: 10.1007/s00262-013-1494-7. Epub 2013 Nov 15. Cancer Immunol Immunother. 2014. PMID: 24233342 Free PMC article.
-
Tapasin decreases immune responsiveness to a model tumor antigen.J Clin Immunol. 2004 Jul;24(4):462-70. doi: 10.1023/B:JOCI.0000029118.51587.d9. J Clin Immunol. 2004. PMID: 15163903
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous